LOGC · Insider Trading
CONTEXTLOGIC HOLDINGS INC
Every open-market purchase and sale reported by LOGC officers, directors and 10%+ beneficial owners on SEC Form 4, which must be filed within two business days of the transaction. Sales often reflect scheduled 10b5-1 plans or tax withholding rather than a directional view, so read counts alongside the size and the filer.
| Filed | Insider | Role | Type | Shares | Value |
|---|---|---|---|---|---|
| 2025-05-19 | Brett Just | Chief Financial Officer | MIXED | +3,165 | −$24.46K |
| 2025-05-08 | Rishi Bajaj | Chief Executive Officer | MIXED | +31,134 | −$171.82K |
| 2025-04-21 | Michael Farlekas | Director | M | +25,684 | — |
| 2025-04-21 | Marshall Heinberg | Director | M | +25,684 | — |
| 2025-04-02 | Jennifer Kwon Chou | Director | A | +56,701 deriv. | — |
| 2025-02-19 | Brett Just | Chief Financial Officer | MIXED | +3,177 | −$25.91K |
| 2025-01-17 | Richard S Parisi | Director | A | +45,360 deriv. | — |
| 2025-01-17 | Michael Farlekas | Director | A | +20,775 deriv. | — |
| 2025-01-17 | Elizabeth A. LaPuma | Director | A | +20,775 deriv. | — |
| 2025-01-17 | Marshall Heinberg | Director | A | +44,321 deriv. | — |
| 2024-12-09 | Michael Farlekas | Director | A | +64,801 deriv. | — |
| 2024-12-09 | Elizabeth A. LaPuma | Director | A | +64,801 deriv. | — |
| 2024-12-09 | Marshall Heinberg | Director | A | +64,801 deriv. | — |
| 2024-12-09 | Richard S Parisi | Director | A | +64,801 deriv. | — |
| 2024-11-19 | Brett Just | Chief Financial Officer | MIXED | +3,149 | −$20.93K |
| 2024-08-19 | Brett Just | Chief Financial Officer | MIXED | +3,157 | −$17.93K |
| 2024-07-02 | Joanna Forster | General Counsel & CCO | MIXED | +30,428 | −$182.49K |
| 2024-05-17 | Brett Just | Chief Financial Officer | MIXED | +4,251 | −$24.64K |
| 2022-11-17 | Jeff Goater | Director | D | −12,500 deriv. | — |
| 2022-11-17 | Daphne Karydas | Director | D | −12,500 deriv. | — |
| 2022-11-17 | Daniel Gruskin | Chief Medical Officer | D | −3,331 | — |
| 2022-11-17 | Mark J Enyedy | Director | D | −2,921 | — |
| 2022-11-17 | Michael S Wyzga | Director | D | −3,141 | — |
| 2022-11-17 | Susan Kahn | Director | D | −12,500 deriv. | — |
| 2022-11-17 | Richard A Moscicki | Director | D | −3,916 | — |
| 2022-11-17 | Mariana Nacht | Chief Scientific Officer | D | −100,000 deriv. | — |
| 2022-11-17 | Leon Chen | Director | D | −22,333 | — |
| 2022-11-17 | Frederic Chereau | President, CEO | D | −253,811 | — |
| 2022-11-17 | Mark A Kay | Director | D | −784,557 | — |
| 2022-07-05 | Daphne Karydas | Director | A | +12,500 deriv. | — |
| 2022-06-21 | Susan Kahn | Director | A | +12,500 deriv. | — |
| 2022-06-21 | Michael S Wyzga | Director | A | +12,500 deriv. | — |
| 2022-06-21 | Jeff Goater | Director | A | +12,500 deriv. | — |
| 2022-06-21 | Mark J Enyedy | Director | A | +12,500 deriv. | — |
| 2022-06-21 | Richard A Moscicki | Director | A | +12,500 deriv. | — |
| 2022-06-21 | Leon Chen | Director | A | +12,500 deriv. | — |
| 2022-06-21 | Mark A Kay | Director | A | +12,500 deriv. | — |
| 2022-03-03 | Cecilia Jones | Chief Financial Officer | A | +112,000 deriv. | — |
| 2022-03-03 | Andrea Paul | General Counsel and Secretary | A | +80,000 deriv. | — |
| 2022-03-03 | Frederic Chereau | President and Chief Executive | A | +328,000 deriv. | — |
| 2022-03-03 | Mariana Nacht | Chief Scientific Officer | A | +100,000 deriv. | — |
| 2022-03-03 | Daniel Gruskin | Chief Medical Officer | A | +140,000 deriv. | — |
| 2022-01-13 | Cecilia Jones | Chief Financial Officer | MIXED | +3,764 | −$4.37K |
| 2021-12-23 | Susan Kahn | Director | A | +25,000 deriv. | — |
| 2021-08-10 | Daniel Gruskin | Chief Medical Officer | MIXED | +3,331 | −$6.38K |
| 2021-06-21 | Mark A Kay | Director | A | +5,000 deriv. | — |
| 2021-06-14 | Michael S Wyzga | Director | A | +12,500 deriv. | — |
| 2021-06-14 | Richard A Moscicki | Director | A | +12,500 deriv. | — |
| 2021-06-14 | Leon Chen | Director | A | +12,500 deriv. | — |
| 2021-06-14 | Jeff Goater | Director | A | +12,500 deriv. | — |
| Insider | Role | Shares Held | Value |
|---|---|---|---|
| Rishi Bajaj | Chief Executive Officer | 51,134 | $361.01K |
| Brett Just | Chief Financial Officer | 29,349 | $207.20K |
| Marshall A Heinberg | Director | 25,684 | $181.33K |
| Michael Farlekas | Director | 25,684 | $181.33K |
Form 4 reports a change in beneficial ownership by an officer, director or 10%+ holder, and must be filed within two business days of the transaction — so this is close to real time, unlike the 45-day-lagged 13F institutional data.
Transaction codes matter more than the raw buy/sell count. Code P is an open-market purchase — an insider choosing to buy with their own money, which is the signal most research treats as informative. Code S is a sale, but sales are frequently pre-scheduled under a 10b5-1 plan or cover tax withholding on vesting equity, so a run of sales often says nothing directional. Codes A and M are grants and option exercises rather than open-market decisions.
Full filing history and per-insider positions are on the LOGC quote page; the site-wide leaderboard is on the insider transactions hub.
Market data may be delayed, incomplete, or inaccurate. Not a recommendation to buy, sell, or hold any security. Verify quotes with your broker before trading. See Terms §17.